Aikido Pharma had KPC-34 Developed at Wake Forest School of Medicine for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).70% of All AML patients are over the age of 60 and only 6.6% of patients are still alive 5 years after diagnosis. Gemcitabine and Cytarabine are the backbone of AML and ALL therapy, but life expectancy is poor and relapses are much harder to treat. Cytarabine (Ara-C) has been a major drug for acute myeloid leukemia (AML) treatment for more than three decades. But KPC34 has shown superior results when tested against Cytarabine. Get in touch with Aikido Pharma today by calling 212-745-1373.
Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics